Danish pharma giant Novo Nordisk launched Ozempic on December 12, 2025, in India. Ozempic is a type 2 diabetes treatment injection known worldwide for its weight loss benefits. It comes in three doses: 0.25 mg, 0.5 mg, and 1 mg, all in an easy-to-use FlexTouch Pen device. The weekly starting price is Rs 2,200, with each pen containing four weekly doses. Patients begin treatment with a 0.25 mg dose for four weeks, costing Rs 8,800 in total. Then, doctors may prescribe a 0.5 mg dose for at least four weeks, priced at Rs 10,170, or a 1 mg maintenance dose that costs Rs 11,175 monthly. Novo Nordisk India Managing Director Vikrant Shrotriya said, "We are very judicious in terms of pricing in India. It really remains very competitive, internally and externally as well, to offer at a price like this." He added, "I would say that it still comes under the affordability zone of the pricing, which is at a range for countries similar to India." Ozempic is Novo Nordisk’s second semaglutide medicine in India after Wegovy, a weight loss drug launched in June 2025. While Wegovy focuses on chronic weight management, Ozempic is marketed solely as a treatment for type 2 diabetes with added weight loss benefits. The company plans to sell Ozempic directly across India, without partners. Its partnership with Emcure Pharma remains only for the weight loss drug Poviztra (semaglutide injection 2.4 mg). The injection will be imported from Denmark. Shrotriya noted supply has been a challenge worldwide due to high demand. "One of the reasons for Ozempic being launched late in India was also to do with ensuring uninterrupted supplies," he said. With the patent for injectable semaglutide expiring next year, generic competitors are expected. However, Novo Nordisk is confident patients will prefer its quality and brand. Ozempic is approved as an add-on to diet and exercise for adults with uncontrolled type 2 diabetes. According to WHO 2023-24 data, India has 101 million diabetes patients, the second largest diabetic population globally, plus 136 million with prediabetes and 254 million with obesity. This highlights the urgent need for effective diabetes treatments like Ozempic.